Increased wakefulness, motor activity and decreased theta activity after blockade of the 5‐HT2B receptor by the subtype‐selective antagonist SB‐215505

• Published in: British journal of pharmacology Vol. 142; no. 8; pp. 1332 - 1342
• Main Authors: Kantor, Sandor, Jakus, Rita, Balogh, Brigitta, Benko, Anita, Bagdy, Gyorgy
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.08.2004; Nature Publishing
• Subjects: 5‐HT2B receptor; Animals; Biological and medical sciences; Dose-Response Relationship, Drug; EEG analysis; fast Fourier transformation; Indoles - pharmacology; Male; Medical sciences; motor activity; Motor Activity - drug effects; Motor Activity - physiology; Pharmacology. Drug treatments; Quinolines - pharmacology; Rats; Receptor, Serotonin, 5-HT2B - physiology; SB‐215505; Serotonin; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists - pharmacology; sleep; spectral analysis; theta activity; Theta Rhythm - drug effects; vigilance; Wakefulness - drug effects; Wakefulness - physiology; Vigilance; Fourier transformation; Serotonin; fast Fourier transformation; Electrophysiology; Electroencephalography; 5-HT2B receptor; Spectral analysis; motor activity; theta activity; SB-215505; Sleep; EEG analysis; Neurotransmitter; Sleep wake cycle; Antagonist; 5-HT2B serotonin receptor

Serotonin‐2 receptor antagonists, like ritanserin, greatly enhance deep slow wave sleep (SWS‐2) and low‐frequency EEG power in humans and rodents. 5‐HT2A and 5‐HT2C receptors may be involved in these effects, but the role of the 5‐HT2B receptor is still unclear. To investigate the role of the 5‐HT2B...